Navidea Biopharmaceuticals
- In Vitro and In Vivo Diagnostic Substances
- Dublin, Ohio
Compensation history
Top executives at Navidea Biopharmaceuticals received an average of $486K per person in annual compensation from 2006 to 2022.
Average pay of disclosed executives at Navidea Biopharmaceuticals
By year
- 2021
JL$1MJed A. LatkinFormer Chief Executive Officer, Chief Operating Officer and Chief Financial OfficerMR$469KMichael S. RosolChief Medical Officer Principal Executive OfficerEE$237KErika L. EvesVice President, Finance & AdministrationMM$153KMichel MikhailChief Regulatory OfficerJK$147KJoel H. KaufmanFormer Chief Business Officer
Executives
We found 18 executives who work or worked at Navidea Biopharmaceuticals.
Michael Rosol
Navidea Biopharmaceuticals
Chief Medical Officer
Erika Eves
Navidea Biopharmaceuticals
Vice President, Finance & Administration
Michel Mikhail
Navidea Biopharmaceuticals
Chief Regulatory Officer
Jed Latkin
Navidea Biopharmaceuticals
Chief Executive Officer
Joel Kaufman
Navidea Biopharmaceuticals
Former Chief Business Officer
Michael Goldberg
Navidea Biopharmaceuticals
Chief Executive Officer
Frederick Cope
Navidea Biopharmaceuticals
Chief Scientific Officer
Ricardo Gonzalez
Navidea Biopharmaceuticals
Chief Executive Officer
News
Navidea Biopharmaceuticals Chief Medical Officer Michael Rosol's 2022 pay slips 8% to $430K
October 5, 2023
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019
About Navidea Biopharmaceuticals
- Industry classifications
- DivisionManufacturing
- Major groupChemicals And Allied Products
- Industry groupDrugs
- IndustryIn Vitro and In Vivo Diagnostic Substances
- Address4995 Bradenton Avenue, Suite 240, Dublin, Ohio 43017
- Phone6147937500
- Fiscal year endDecember 31
- Former names
- NEOPROBE CORPUntil December 29, 2011
Source: SEC filings on October 5, 2023, October 24, 2022, August 2, 2021, June 28, 2019, May 24, 2017, June 5, 2015, June 6, 2014, May 24, 2013, July 10, 2012, June 11, 2010, May 14, 2009, and May 15, 2008.